Nicotinamide Riboside, a Promising Vitamin B(3) Derivative for Healthy Aging and Longevity: Current Research and Perspectives

Biţă A, Scorei IR, Ciocîlteu MV, Nicolaescu OE, Pîrvu AS, Bejenaru LE, et al. | Molecules | 2023 | Evidence: moderate

View on PubMed → | DOI | Publisher

Plain-language summary

Published 2023 in Molecules, this work by Biţă A and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

Review article in Molecules (2023) summarising the state of NAD+/NMN/sirtuin science
Useful synthesis for understanding mechanism and evidence quality
Cited as reference for NAD+ booster therapeutic claims

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to science decisions, with secondary relevance to compare. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index